Emerging studies suggest Retatru tide , a dual stimulator targeting both incretin and GIP , may offer a notable step forward for weight loss . Early patient tests have indicated considerable losses in abdominal mass , potentially exceeding current obesity medications . However , further assessment is required to thoroughly understand its long-term